Drugs / PD-1/IL-2α-bias bispecific antibody fusion protein
PD-1/IL-2α-bias bispecific antibody fusion protein
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07688291 | Jun 2026 → Jan 2029 expected | esophageal squamous cell carcinoma | Beijing GoBroad Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD-1/IL-2α-bias bispecific antibody fusion protein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07688291 ↗ |
| Modality | Protein / enzyme biologic | “PD-1/IL-2α-bias bispecific antibody fusion protein” NCT07688291 ↗ |